Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
Financial Reports
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Financial Reports
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
31-Oct-2022
Quarterly Activities/Appendix 4C Cash Flow Report
29-Jul-2022
Quarterly Activities/Appendix 4C Cash Flow Report
29-Jul-2022
Quarterly Activities/Appendix 4C Cash Flow Report
2-May-2022
Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting
29-Apr-2022
Quarterly Activities/Appendix 4C Cash Flow Report
23-Feb-2022
Kazia Half Year Accounts and Appx 4D
31-Jan-2022
Quarterly Activities/Appendix 4C Cash Flow Report
1
